You Need to Build Solid IP Value and Investor Confidence
You want to spend the right amount of money to secure the right IP to someday close a deal or secure investor funding – but you don’t want to file in every country in the world and you’d like to know what big biopharma and major investors actually will care about when they conduct due diligence on your IP portfolio.
Biotechnology Intellectual Property Law Strategy
I design intellectual property strategies at an early stage to align my clients’ R&D plans and budgets with an optimal patent and regulatory exclusivity position for their products. And I manage patent portfolios and have extensive experience negotiating collaboration agreements and other technology transactions involving IP. So I know how to build IP value that matters.
Your most valuable IP strategy begins during product development, not afterward
Every product is unique. The state of the art in IP strategy changes and evolves – as recent court decisions and the new patent law and new FDA biologics regulations demonstrate. And strategic considerations are different for small molecules, biologics, devices and diagnostics. So, if you wait to plan your IP strategy until you see what comes out of the lab, then you’ve missed the most crucial opportunity to build asset value and secure the partnerships that will drive ultimate success.
You want to conduct due diligence on another company or prepare your own enterprise for someone else’s due diligence study.
I conduct due diligence studies, both for investors and M&A evaluations – also for corporate boards and management who want to identify and resolve problems in advance or who want to take steps to enhance IP value before a deal is negotiated.